{"filing":{"accession_number":"0001104659-26-077354","cik":"0001813814","ticker":"DFTX","company_name":"Definium Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"tm2618395d3_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/tm2618395d3_8k.htm"},"events":[{"id":13610,"run_id":12087,"accession_number":"0001104659-26-077354","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Definium entered into an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00 per share, with underwriters exercising their full option for an additional 3,088,235 shares, generating approximately $805 million in gross proceeds. This registered public offering will dilute existing shareholders materially.","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10793,"accession_number":"0001104659-26-077354","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Definium entered into an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00 per share, with underwriters exercising their full option for an additional 3,088,235 shares, generating approximately $805 million in gross proceeds. This is a material registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not unregistered), the core event is the issuance of a substantial number of new common shares to raise capital, which is the defining characteristic of a dilutive equity issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:15:55.547529+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10794,"accession_number":"0001104659-26-077354","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Definium announced a public offering of common shares priced at $34.00 per share, with gross proceeds of approximately $700 million (20,588,236 shares). This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits document both the announcement of the proposed offering (June 22) and the pricing (June 23), with expected closing on June 25, 2026. This is a material capital-raising event typical of dilutive equity issuances disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:15:55.547529+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10793,"accession_number":"0001104659-26-077354","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Definium entered into an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00 per share, with underwriters exercising their full option for an additional 3,088,235 shares, generating approximately $805 million in gross proceeds. This is a material registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not unregistered), the core event is the issuance of a substantial number of new common shares to raise capital, which is the defining characteristic of a dilutive equity issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:15:55.547529+00:00","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-24"},{"id":10794,"accession_number":"0001104659-26-077354","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Definium announced a public offering of common shares priced at $34.00 per share, with gross proceeds of approximately $700 million (20,588,236 shares). This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits document both the announcement of the proposed offering (June 22) and the pricing (June 23), with expected closing on June 25, 2026. This is a material capital-raising event typical of dilutive equity issuances disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:15:55.547529+00:00","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-24"}]}